Search for:

About
Product Portfolio
Partners
Science
- Medical information U.S.
- Publications
Investors
Join Our Team
Contact Us
- Contact Us
- Locations

Shopping cart close

About
Product Portfolio
Partners
Science
- Medical information U.S.
- Publications
Investors
Join Our Team
Contact Us
- Contact Us
- Locations

Blog

Home » SEC FIlings »

14 Mar

Post-Effective amendments for registration statement

March 14, 2023
Posted by Ulisses

Close

Recent Posts

Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
March 14, 2024 No Comments
Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
March 14, 2024 No Comments
Scilex Holding Company Announces Closing of $10 Million Bought Deal Offering
March 5, 2024 No Comments
Scilex Holding Company Sets Launch Price of $595 per 150ml bottle of Gloperba®, its First and Only Liquid Oral Version of the Anti-Gout Medicine Colchicine Indicated for the Prophylaxis of Painful Gout Flares in Adults; Expected Plans to Launch in the First Half of 2024
March 5, 2024 No Comments
Scilex Holding Company Launches New Website to Showcase Growing Portfolio of Non-Opioid Products and Pipeline Information Updates
March 4, 2024 No Comments

Terms of Use Privacy Policy Contact

Follow us on Facebook
Follow us on LinkedIn
Contact us by email

©2024 Scilex Holding All Rights Reserved
Scilex Holding Company is the owner of Scilex Pharmaceuticals and Semnur Pharmaceuticals

Scroll To Top Sidebar

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

Accept More info